Assembly Biosciences (ASMB) Receives Media Sentiment Rating of 0.19

News coverage about Assembly Biosciences (NASDAQ:ASMB) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Assembly Biosciences earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.6123853202068 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

These are some of the news stories that may have effected Accern Sentiment’s scoring:

How to Become a New Pot Stock Millionaire

Assembly Biosciences stock opened at $44.61 on Friday. Assembly Biosciences has a one year low of $18.60 and a one year high of $67.36.

A number of research analysts have recently issued reports on ASMB shares. B. Riley started coverage on Assembly Biosciences in a report on Friday, January 5th. They set a “neutral” rating and a $35.00 price target on the stock. BidaskClub downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Saturday, January 6th. Zacks Investment Research downgraded Assembly Biosciences from a “buy” rating to a “hold” rating in a report on Monday, January 15th. ValuEngine raised Assembly Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 3rd. Finally, Jefferies Group upped their price target on Assembly Biosciences to $75.00 and gave the company a “buy” rating in a report on Thursday, March 8th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $54.25.

In related news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $56.37, for a total transaction of $56,370.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 3,000 shares of company stock valued at $152,550. 19.60% of the stock is owned by company insiders.

WARNING: “Assembly Biosciences (ASMB) Receives Media Sentiment Rating of 0.19” was published by Ticker Report and is owned by of Ticker Report. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3337378/assembly-biosciences-asmb-receives-media-sentiment-rating-of-0-19.html.

About Assembly Biosciences

Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.

Insider Buying and Selling by Quarter for Assembly Biosciences (NASDAQ:ASMB)

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

New Age Beverages  Stock Price Down 9.4% on Analyst Downgrade
New Age Beverages Stock Price Down 9.4% on Analyst Downgrade
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
Scotiabank Reiterates C$4.75 Price Target for Premier Gold Mines
BMO Capital Markets Increases Roots  Price Target to C$16.00
BMO Capital Markets Increases Roots Price Target to C$16.00
Syntel  Trading -0.6% Higher  After Strong Earnings
Syntel Trading -0.6% Higher After Strong Earnings
BNP Paribas Reiterates CHF 74 Price Target for Nestle
BNP Paribas Reiterates CHF 74 Price Target for Nestle
Roche  Given a CHF 230 Price Target at Morgan Stanley
Roche Given a CHF 230 Price Target at Morgan Stanley


Leave a Reply

© 2006-2018 Ticker Report. Google+.